Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcatheter Mitral Valve-in-Valve Replacement With Microaxial Flow-Pump Support for Bioprosthetic Valve Failure.

JACC. Case reports·2026
Same author

Erratum to 2025 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Surgical management of acute myocardial infarction and associated complications: The Journal of Thoracic and Cardiovascular Surgery, Volume 170, Issue 5, 2025, Pages 1327-1344.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Machine Learning Based Prediction of Hospital Mortality in Post-Cardiotomy Cardiogenic Shock with Mechanical Support.

ESC heart failure·2026
Same author

Local Anesthesia and Analgosedation for Surgical Micro-Axial Flow Pump Implantation.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Impact of Partial- to Full-Support Escalation With Microaxial Flow Pumps Prior to Durable Left Ventricular Assist Device Implantation.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

Impact of Gentamicin-Impregnated Collagen Sponge on the Incidence of Access Related Infections After Full-Support Microaxial Flow Pump Therapy.

Artificial organs·2026

Related Experiment Video

Updated: Jun 3, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Mechanical circulatory support-results, developments and trends.

Thomas Krabatsch1, Martin Schweiger, Alexander Stepanenko

  • 1Deutsches Herzzentrum Berlin, Department of Cardiovascular and Thoracic Surgery, Germany. krabatsch@dhzb.de

Journal of Cardiovascular Translational Research
|March 12, 2011
PubMed
Summary
This summary is machine-generated.

Ventricular assist devices (VADs) are increasingly used for end-stage heart failure. Modern VADs, primarily continuous-flow rotary pumps, show growing acceptance and decreasing complications, establishing them as a key treatment option.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Experiment Videos

Last Updated: Jun 3, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • Ventricular assist devices (VADs) are crucial for end-stage heart failure.
  • VAD implantation numbers are rising globally.
  • Technological advancements have shifted VAD types.

Purpose of the Study:

  • To analyze trends and outcomes of VAD implantation over a significant period.
  • To evaluate the evolving role of different VAD types.
  • To assess the success of VADs in bridging patients to transplantation or recovery.

Main Methods:

  • Retrospective analysis of 1,598 VAD implantations in 1,455 patients from July 1987 to July 2010.
  • Categorization of VADs by type (left, biventricular, right ventricular) and pump technology (pulsatile vs. continuous-flow).
  • Review of patient demographics, indications for VAD, support duration, and outcomes (transplantation, explantation, discharge).

Main Results:

  • The majority of patients were male (81.0%) with a mean age of 49.4 years.
  • Cardiomyopathy was the leading indication (n=1,074).
  • Continuous-flow pumps now constitute over 95% of implants, with a decrease in biventricular VADs to 20% by 2009.
  • 347 patients were bridged to transplantation, and 122 achieved myocardial recovery.
  • 31.4% of patients received VADs for permanent support in 2009, with 521 discharged.

Conclusions:

  • VAD implantation is an established treatment for acute and chronic end-stage heart failure.
  • Second and third-generation left ventricular assist devices are widely used globally.
  • VAD therapy demonstrates growing acceptance, decreasing complications, and improved patient outcomes.